“drugs” Archives

in
Entry Author Date Location
With New Data, Medicines Co. Takes Long-Lasting Heart Drug to Phase 3 11/15/16 New York
Corbus Shares Climb on Early Data For Inflammation Drug 11/14/16 Boston
New Data Show Biogen, Ionis Drug Might Help More With Rare Spine Disease 11/07/16 Boston
Verastem Takes a Low-Cost Flier on Infinity’s Blood Cancer Drug 11/02/16 Boston
Celldex, Aiming For More Cancer Drug Combos, Pays $62.5M For Kolltan 11/01/16 New York
On Front Lines Of Price Dispute, Eye Doctors Wary of New Drug Data 11/01/16 National
Allergan Snags Rhythm’s Diabetes-Related GI Drug for $200M 10/27/16 Boston
Alkermes Eyes FDA Nod After Retooled Study Yields Desired Results 10/20/16 Boston
Roundup: J&J and AT&T Grow in Houston, Inspyr and Meshify Move On 10/19/16 Texas
Early Data for Celgene’s Oral Crohn’s Drug Gets Mixed Reaction 10/17/16 New York
Weeks After Deal, FDA Slaps Clinical Hold on Regeneron/Teva Pain Drug 10/17/16 New York
Bio Roundup: Bristol & Illumina Blues, Sickle Cell News & More 10/14/16 National
California Accelerators Enroll Startups Targeting Cannabis Industry 10/12/16 San Diego
IT-Biotech Hybrid Zymergen Raises $130M Round Led By SoftBank 10/11/16 San Francisco
San Diego Startups Raise $287M in Third Quarter, and Top 10 Deals 10/11/16 San Diego
How Doctors Think About Drug Prices 10/11/16 Boston
Defying Patient Pressure, Anthem Says No to Sarepta’s Duchenne Drug 10/07/16 Boston
Post FDA Approval, Sarepta Wheels and Deals for Combo Duchenne Drugs 10/04/16 Boston
Still Stuck Below IPO Price, Merrimack Restructures, CEO Resigns 10/03/16 Boston
Gates Grant Helps Sirenas Extend Hunt for Drugs From Sea Organisms 10/03/16 San Diego
Taking Aim at Alexion, Ra Pharma Heads to IPO Queue 10/03/16 Boston
Intra-Cellular Shares Sink As Schizophrenia Drug Flunks Final Test 09/28/16 New York
The Future of Innovation at Xconomy’s Upcoming Disruptors Event 09/28/16 Texas
Avalon Leads $18M in Early Funding for Cancer Immunotherapy Startup 09/27/16 San Diego
In Turnaround Saga, Ignyta Nears Crucial Phase in Cancer Drug Trial 09/23/16 San Diego
Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug 09/22/16 Boston
Eleven Bio Buys Viventia, Rebrands as Cancer Drug Developer 09/21/16 Boston
Regeneron, in Pain Drug Race With Pfizer & Lilly, Gets $250M From Teva 09/20/16 New York
Pharmaceutical Price Controls Might Be Closer Than You Think 09/20/16 San Diego
Sarepta Prices $300K Duchenne Drug As FDA Rift Emerges Over Approval 09/19/16 Boston
Page 4 of 94 « previous page · next page »